toxylact: a04ad10 Dronabinol

The first professional lActological database in the word

Dronabinol (ATC A04AD10) is a synthetic cannabinoid antiemetic and appetite stimulant that is contraindicated in breastfeeding due to psychoactive central nervous system effects and insufficient safety data in lactating women and infants.medpedia.framar+5

ATC class and pharmacological profile

Dronabinol is the pharmaceutical name for synthetic delta‑9‑tetrahydrocannabinol (THC), classified in ATC group A04AD10 “Other antiemetics and antinauseants” within the gastrointestinal system and metabolism section.wikipedia+3
It acts as a partial agonist at cannabinoid CB1 receptors in the central nervous system and gastrointestinal tract, modulating neurotransmitter release and inhibiting emetic signaling pathways.ncbi.nlm.nih+2
Antiemetic effects are mediated through CB1‑dependent inhibition of 5‑HT3 (serotonin) receptors and reduced gastrointestinal motility, while psychoactive effects reflect its CNS cannabinoid activity.cannabisevidence+1

Indications in adults

ATC A04AD10 medicines containing dronabinol are indicated for anorexia associated with weight loss in patients with AIDS and for nausea and vomiting associated with cancer chemotherapy in adults who have failed standard antiemetic therapy.camberpharma+5
Appetite stimulation and reduction of nausea and emesis are the clinically relevant therapeutic outcomes.rcsb+3
Off‑label use has been explored for obstructive sleep apnea and other conditions, but these indications remain investigational and are not part of the formal A04AD10 class labeling.prescriberpoint+1

Dosage and administration (non‑lactation)

Dronabinol is administered orally as capsules or oral solution, usually starting at 2.5 mg twice daily for AIDS‑related anorexia, with titration in small increments based on clinical response and tolerability.medpedia.framar+2
In chemotherapy‑induced nausea and vomiting, dosing is weight‑based (mg/m²), initiated 1–3 hours before chemotherapy and repeated every 2–4 hours, up to 4–6 doses per day, with maximum single doses around 12.6–15 mg/m² depending on formulation.ncbi.nlm.nih+2
Marked interindividual variability in pharmacodynamic effects requires cautious titration and close monitoring, especially in the elderly and in patients with cardiovascular or psychiatric comorbidities.camberpharma+2

Toxicological profile

Dronabinol produces dose‑related central nervous system toxicity with neuropsychiatric manifestations such as dizziness, euphoria, anxiety, paranoia, hallucinations, depersonalization, and abnormal thinking.accessdata.fda+4
Sedation, somnolence, ataxia, and visual disturbances (including blurred vision) are common and may impair psychomotor performance and driving ability.pdf.hres+3
Cardiovascular effects include tachycardia, orthostatic hypotension, and potential exacerbation of underlying heart disease, necessitating caution in patients with cardiovascular disorders.pdf.hres+2

From a broader toxicological perspective, chronic exposure to THC‑containing products has been associated with cognitive impairment, mood changes, and potential effects on brain development, which are of particular concern for fetuses and infants.fda+1
Overdose may present with severe anxiety, agitation, psychosis‑like symptoms, marked tachycardia, and pronounced neurocognitive impairment; management is supportive with close observation and symptomatic treatment.ncbi.nlm.nih+2
Dependence and misuse potential exist due to psychoactive properties, although dronabinol is typically prescribed under controlled conditions for limited indications.accessdata.fda+2

Contraindications and precautions (general)

Dronabinol is contraindicated in patients with known hypersensitivity to the active substance or formulation components.medpedia.framar+2
It should be used with great caution in individuals with psychiatric disorders (e.g. psychosis, severe anxiety), in those with significant cardiovascular disease, and in older adults, where CNS adverse effects are more frequent and severe.camberpharma+2
Concomitant CNS depressants (e.g. benzodiazepines, opioids, alcohol) may potentiate sedation and psychomotor impairment, increasing overall toxicity risk.pdf.hres+2

Lactation and breastfeeding risk assessment

Transfer into breast milk and infant exposure

THC and THC‑like cannabinoids, including dronabinol, are lipophilic and distribute into fatty tissues and human milk, with detectable levels in breast milk for several days after maternal use.lllc+1
Available data suggest that breast milk can contain measurable THC up to approximately 6 days after maternal consumption, indicating prolonged potential exposure for the breastfed infant.cdc
Although direct quantitative pharmacokinetic data for synthetic dronabinol in human milk are limited, extrapolation from cannabis and THC studies strongly supports milk transfer and infant exposure.pubmed.ncbi.nlm.nih+3

Effects on the breastfed infant

Robust, controlled studies of dronabinol in breastfeeding dyads are lacking, and current evidence does not conclusively define a safe exposure threshold for infants.pubmed.ncbi.nlm.nih+2
Potential infant risks inferred from THC data include adverse effects on neurodevelopment, such as impaired cognition, altered behavior, and long‑term consequences related to disrupted brain maturation.fda+1
Minor acute effects such as sedation, feeding difficulties, or altered responsiveness are considered biologically plausible given the drug’s CNS activity, but have not been adequately characterized in systematic lactation studies.lllc+2

Maternal safety during lactation

In lactating women, dronabinol may impair judgment, reaction time, and psychomotor skills, which can compromise safe infant care.cdc+3
Neuropsychiatric adverse reactions (anxiety, paranoia, hallucinations, depersonalization) pose additional risks for the mother–infant interaction and caregiving quality.medpedia.framar+3
Given the absence of clear therapeutic indications in the postpartum period that outweigh these risks, routine use in breastfeeding mothers is not justified.pubmed.ncbi.nlm.nih+3

Recommendations from authorities and professional bodies

Regulatory authorities and expert organizations strongly advise against the use of THC‑containing products, including prescription dronabinol, during pregnancy and breastfeeding.lllc+3
The U.S. FDA explicitly recommends avoiding THC and dronabinol in all forms while breastfeeding, citing potential serious risks and lack of adequate safety data.fda
Public health agencies emphasize that, due to insufficient evidence of safety and plausible harm, breastfeeding mothers should refrain from cannabis and cannabinoid use; if use persists, at minimum a substantial reduction in dose and avoidance of infant second‑hand smoke exposure are advised.cdc+2

Toxicological‑lactological classification for A04AD10 (dronabinol)

For your database, the overall toxicological‑lactological assessment for dronabinol‑containing medicines in ATC class A04AD10 can be summarized as follows:ncbi.nlm.nih+6

·        Lactation safety category: Contraindicated / not recommended in breastfeeding.

·        Primary concern: Psychoactive CNS effects and potential negative impact on infant neurodevelopment; transfer of lipophilic THC‑like compound into breast milk with days‑long detectability.

·        Use in breastfeeding: Avoid; if maternal cannabinoid exposure cannot be prevented, individualized counseling must weigh the benefits of breastfeeding against unquantified but plausible neurodevelopmental risks, with close infant monitoring.

·        Preferred alternatives: For chemotherapy‑induced nausea and vomiting in lactating women, evidence‑based non‑cannabinoid antiemetics (e.g. serotonin 5‑HT3 antagonists, dopamine antagonists, antihistamines) should be considered according to oncology and lactation guidelines.atcddd.fhi+1

Brief example clinical statement

“In lactating women, dronabinol‑containing antiemetic therapy is not recommended because of infant exposure to a psychoactive cannabinoid via breast milk and the absence of reassuring safety data; alternative non‑cannabinoid antiemetics are preferred.”

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.